文献速递前列腺癌

识别局灶治疗的最佳候选者:一项综合综述

Identifying the best candidate for focal therapy: a comprehensive review.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-10-23

该综述系统检索截至2023年12月31日的PubMed文献,定性总结局灶治疗(FT)治疗局限性前列腺癌(PCa)的患者选择标准。目前无I级证据;国际多学科共识推荐所有候选者行多参数磁共振成像(mpMRI)后行MRI靶向与系统穿刺;FT可考虑用于临床局限性、中危(Gleason 3+4和4+3)且 preferably 单灶病变、预期寿命可接受的患者;前列腺体积>50 ml和勃起功能障碍者不应被排除;推荐PSA<20(理想<10)ng/mL。

要点

  • 无I级证据支持FT最佳患者选择方法。
  • 共识推荐所有候选者行mpMRI后MRI靶向与系统穿刺。
  • FT可考虑用于临床局限性、中危、preferably单灶病变患者。

核心结论

  • FT可考虑用于经过良好选择的局限性PCa患者。
  • 本综述提供了关于FT患者选择最佳方法的综合见解。

研究设计与样本

  • 系统检索PubMed数据库截至2023年12月31日报告FT患者选择标准的研究,排除不相关文章并经质量评估后提取数据,定性描述结果。

主要发现

  • 目前无I级证据关于PCa患者FT的最佳患者选择方法。
  • 当前国际多学科共识声明推荐所有候选者行mpMRI后行MRI靶向和系统穿刺。
  • FT可考虑用于临床局限性、中危(Gleason 3+4和4+3)且preferably单灶病变的患者。
  • 患者应有可接受的预期寿命。
  • 前列腺体积>50 ml和勃起功能障碍的患者不应被排除在FT之外。

关键数值与推荐

  • 当前国际多学科共识声明推荐所有候选者行mpMRI后行MRI靶向和系统穿刺。
  • FT可考虑用于临床局限性、中危(Gleason 3+4和4+3)且preferably单灶病变的患者。
  • 患者应有可接受的预期寿命。
  • 前列腺体积>50 ml和勃起功能障碍的患者不应被排除在FT之外。
  • 推荐PSA水平<20(理想<10)ng/mL。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the evidence supporting the use of focal therapy (FT) in patients with localized prostate cancer (PCa), considerable variability exists in the patient selection criteria across current studies. This study aims to review the most recent evidence concerning the optimal approach to patient selection for FT in PCa. METHODS: PubMed database was systematically queried for studies reporting patient selection criteria in FT for PCa before December 31, 2023. After excluding non-relevant articles and a quality assessment, data were extracted, and results were described qualitatively. RESULTS: There is no level I evidence regarding the best patient selection approach for FT in patients with PCa. Current international multidisciplinary consensus statements recommend multiparametric magnetic resonance imaging (mpMRI) followed by MRI-targeted and systematic biopsy for all candidates. FT may be considered in clinically localized, intermediate risk (Gleason 3 + 4 and 4 + 3), and preferably unifocal disease. Patients should have an acceptable life expectancy. Those with prostate volume >50 ml and erectile dysfunction should not be excluded from FT. Prostate-specific antigen (PSA) level of < 20 (ideally < 10) ng/mL is recommended. However, the utility of other molecular and genomic biomarkers in patient selection for FT remains unknown. CONCLUSIONS: FT may be considered in well-selected patients with localized PCa. This review provides a comprehensive insight regarding the optimal approach for patient selection in FT.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ghoreifi A, Gomella L, Hu JC, et al. Identifying the best candidate for focal therapy: a comprehensive review. Prostate Cancer Prostatic Dis. 2024. PMID: 39443815. doi:10.1038/s41391-024-00907-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。